Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

This study is testing a new experimental pill called silmitasertib alongside standard chemotherapy drugs for children and young adults with certain types of solid tumors. Researchers want to find the safest and most effective dose of this new drug combination to help patients whose cancer has returned or has not responded to previous treatments.

This study is open to children and young adults under 30 years old who have been diagnosed with specific cancers like neuroblastoma or Ewing sarcoma that have come back or stopped responding to past treatments. Participants must also not be taking certain medications like statins or blood thinners, and must be finished with other experimental drugs.

Participants will take the investigational pill silmitasertib by mouth along with standard chemotherapy medications like irinotecan, temozolomide, or vincristine. Doctors will closely monitor their safety, check how well the body tolerates the treatment, and see how the cancer responds over time.

The study is currently recruiting patients and is taking place at multiple medical centers in cities such as Birmingham, Phoenix, and Oakland within the United States.